Abstract Library

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites

Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Mamodaly M, Chen R, Cazes A, Guedj N, Deschamps L,

Keywords: Neuroendocrine markers, Chromogranin A, Chromogranin B, INSM1,

#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?

Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,

Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,

#1441 Epidemiology and Treatment Strategy of Neuroendocrine Neoplasms in North China

Introduction: Few studies had focus on the epidemiology of neuroendocrine neoplasms (NENs) , a rare disease, in China.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Wang Q

Authors: Wang Q, Jia R, Chen Y, Zhao C, Ge F,

Keywords: neuroendocrine neoplasms,clinical pathological features,treatment strategy,

#1434 CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors

Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Luo G

Authors: Luo G, Guo M, Liu Z, Liu C, Cheng H,

Keywords: pNET, prognosis, CA19-9, biomarker,